CN1990032B - 灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 - Google Patents
灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 Download PDFInfo
- Publication number
- CN1990032B CN1990032B CN2005101353571A CN200510135357A CN1990032B CN 1990032 B CN1990032 B CN 1990032B CN 2005101353571 A CN2005101353571 A CN 2005101353571A CN 200510135357 A CN200510135357 A CN 200510135357A CN 1990032 B CN1990032 B CN 1990032B
- Authority
- CN
- China
- Prior art keywords
- oil
- injection
- water
- ganoderma spore
- emulsion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 62
- 239000000839 emulsion Substances 0.000 title claims abstract description 45
- 238000010253 intravenous injection Methods 0.000 title claims abstract description 25
- 239000002131 composite material Substances 0.000 title claims abstract description 24
- 238000000034 method Methods 0.000 title claims description 10
- 244000077995 Coix lacryma jobi Species 0.000 title abstract 3
- 235000019198 oils Nutrition 0.000 title abstract 3
- 235000015112 vegetable and seed oil Nutrition 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 22
- 238000002347 injection Methods 0.000 claims abstract description 22
- 239000007924 injection Substances 0.000 claims abstract description 22
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 20
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 8
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 59
- 210000000582 semen Anatomy 0.000 claims description 54
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 36
- 238000003756 stirring Methods 0.000 claims description 36
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 33
- 238000002360 preparation method Methods 0.000 claims description 32
- 239000012071 phase Substances 0.000 claims description 30
- 230000001804 emulsifying effect Effects 0.000 claims description 29
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 24
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 24
- 210000003022 colostrum Anatomy 0.000 claims description 24
- 235000021277 colostrum Nutrition 0.000 claims description 24
- 239000000243 solution Substances 0.000 claims description 22
- 239000008215 water for injection Substances 0.000 claims description 22
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 15
- 229960001295 tocopherol Drugs 0.000 claims description 15
- 229930003799 tocopherol Natural products 0.000 claims description 15
- 235000010384 tocopherol Nutrition 0.000 claims description 15
- 239000011732 tocopherol Substances 0.000 claims description 15
- 210000003462 vein Anatomy 0.000 claims description 15
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 14
- 210000000481 breast Anatomy 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 238000004945 emulsification Methods 0.000 claims description 13
- 238000004659 sterilization and disinfection Methods 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 238000012856 packing Methods 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 11
- 230000001105 regulatory effect Effects 0.000 claims description 10
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 6
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 239000006185 dispersion Substances 0.000 claims description 6
- 239000008347 soybean phospholipid Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 238000011068 loading method Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 235000001727 glucose Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 229920001993 poloxamer 188 Polymers 0.000 claims description 3
- 229940044519 poloxamer 188 Drugs 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- 235000010356 sorbitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 239000008346 aqueous phase Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000010494 opalescence Effects 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 125000002640 tocopherol group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 235000006708 antioxidants Nutrition 0.000 abstract 1
- 230000003750 conditioning effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000005303 weighing Methods 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 230000036039 immunity Effects 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000036436 anti-hiv Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 1
- 244000020998 Acacia farnesiana Species 0.000 description 1
- 235000003074 Acacia farnesiana Nutrition 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000007487 gallbladder carcinoma Diseases 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000004637 gastric cardia carcinoma Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101353571A CN1990032B (zh) | 2005-12-31 | 2005-12-31 | 灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005101353571A CN1990032B (zh) | 2005-12-31 | 2005-12-31 | 灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1990032A CN1990032A (zh) | 2007-07-04 |
CN1990032B true CN1990032B (zh) | 2011-03-23 |
Family
ID=38212713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2005101353571A Expired - Fee Related CN1990032B (zh) | 2005-12-31 | 2005-12-31 | 灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1990032B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102641448B (zh) * | 2012-05-15 | 2013-11-20 | 江苏省中医药研究院 | 抗肺癌中药组合物、其制备方法及其在制备抗肺癌药物中的应用 |
CN103040914A (zh) * | 2013-01-22 | 2013-04-17 | 湖南奇异生物科技有限公司 | 杜仲籽油纳米乳注射液的制备方法 |
CN105663282B (zh) * | 2016-02-17 | 2018-03-30 | 广州欧化药业有限公司 | 一种牡丹籽油脂肪乳剂及其制备方法 |
CN109432002A (zh) * | 2018-12-25 | 2019-03-08 | 广州白云山汉方现代药业有限公司 | 一种阿瑞匹坦乳剂及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1080176A (zh) * | 1993-01-01 | 1994-01-05 | 浙江省中医院 | 薏苡仁中性油脂乳剂 |
CN1175463A (zh) * | 1994-10-22 | 1998-03-11 | 李大鹏 | 抗衰老降血脂的中药药酒 |
CN1440782A (zh) * | 2003-03-28 | 2003-09-10 | 沈阳药科大学 | 一种含有薏苡仁油及鸦胆子油复合纳米乳剂的制备工艺及配方 |
CN1616074A (zh) * | 2004-09-29 | 2005-05-18 | 广州汉方现代中药研究开发有限公司 | 灵芝孢子油脂肪乳剂 |
-
2005
- 2005-12-31 CN CN2005101353571A patent/CN1990032B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1080176A (zh) * | 1993-01-01 | 1994-01-05 | 浙江省中医院 | 薏苡仁中性油脂乳剂 |
CN1175463A (zh) * | 1994-10-22 | 1998-03-11 | 李大鹏 | 抗衰老降血脂的中药药酒 |
CN1440782A (zh) * | 2003-03-28 | 2003-09-10 | 沈阳药科大学 | 一种含有薏苡仁油及鸦胆子油复合纳米乳剂的制备工艺及配方 |
CN1616074A (zh) * | 2004-09-29 | 2005-05-18 | 广州汉方现代中药研究开发有限公司 | 灵芝孢子油脂肪乳剂 |
Non-Patent Citations (2)
Title |
---|
CN 1080176 A,全文. |
赵新先.中药注射剂学.广东科技出版社,2000,273-288. * |
Also Published As
Publication number | Publication date |
---|---|
CN1990032A (zh) | 2007-07-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1736369A (zh) | 姜黄素乳剂及其制备方法和用途 | |
CN101288642B (zh) | 一种紫杉烷类药物静脉给药制剂及其制备方法 | |
CN1990032B (zh) | 灵芝孢子油与薏苡仁油复合静脉注射乳剂及其制备方法 | |
CN1857334B (zh) | 灵芝孢子油静脉乳注射液及其制备方法 | |
CN101601649B (zh) | 一种乌苯美司脂肪乳注射液及其制备方法 | |
CN101474150B (zh) | 一种稳定的前列地尔注射乳液及其制备方法 | |
CN105456200A (zh) | 一种提高难溶性药物口服生物利用度的纳米粒微球的制备方法及应用 | |
CN1813733A (zh) | 维生素e烟酸酯脂质微球注射液及其制备方法 | |
CN101147727A (zh) | 莪术醇亚微乳及其制备方法和制剂 | |
CN105663282B (zh) | 一种牡丹籽油脂肪乳剂及其制备方法 | |
CN101491550A (zh) | 一种红曲提取物与辅酶q10复方制剂及其制备方法 | |
CN1225242C (zh) | 一种抗肿瘤药物毛兰素脂肪乳剂及其制备方法 | |
CN100998867A (zh) | 抗癌中药复方纳米乳剂及其制备方法 | |
CN103735555B (zh) | 一种葫芦素药物组合物及其制药用途 | |
CN100377712C (zh) | 葫芦素脂质体组方及其制剂 | |
CN105381469A (zh) | 一种用于治疗脑部疾病的药物制剂 | |
CN1250273C (zh) | 治疗脑癌的蛇毒胶囊及制备方法 | |
CN1562014A (zh) | 注射用ve烟酸酯乳剂及其制备方法 | |
CN1057220C (zh) | 一种复方抗癌中药 | |
CN109498547A (zh) | 一种平阳霉素局部注射制剂及其制备方法 | |
CN1919190A (zh) | 紫杉醇与中药挥发油复合静脉注射乳剂及其制备方法 | |
CN115006347B (zh) | 一种D-半乳糖修饰的α-亚麻酸肝靶向纳米乳液及其制备方法和应用 | |
CN109432004A (zh) | 一种脂肪乳注射液的制备方法 | |
CN112007025B (zh) | 米拉贝隆在制备预防和/或治疗恶性肿瘤的药物中的应用 | |
CN1931158A (zh) | 多西他赛与中药挥发油复合静脉注射乳剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin science and Technology Park of Beichen Xinyi Road Liaohe Road No. 1 white Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110323 Termination date: 20171231 |
|
CF01 | Termination of patent right due to non-payment of annual fee |